Ascendis Pharma A (ASND) Profit After Tax (2014 - 2026)

Ascendis Pharma A has disclosed Profit After Tax across 13 years of filings, most recently posting $736.8 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at $736.8 million, up 640.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $582.4 million (up 765.75% YoY), and the FY2025 annual result was -$265.4 million, up 34.3% from the prior year.
• Profit After Tax came in at $736.8 million for Q1 2026 at Ascendis Pharma A, up from -$39.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $736.8 million in Q1 2026 to a low of -$211.6 million in Q4 2022.
• The 5-year median for Profit After Tax is -$71.3 million (2025), against an average of -$3.4 million.
• Across the five-year window, Profit After Tax plunged 184.52% in 2023 and surged 640.23% in 2026, its largest moves.
• Ascendis Pharma A's Profit After Tax stood at -$211.6 million in 2022, then surged by 55.83% to -$93.5 million in 2023, then soared by 56.02% to -$41.1 million in 2024, then gained by 4.96% to -$39.1 million in 2025, then soared by 1985.95% to $736.8 million in 2026.
• The last three Profit After Tax figures came in at $736.8 million (Q1 2026), -$39.1 million (Q4 2025), and -$71.3 million (Q3 2025), per Business Quant data.